Megan's Mission Foundation Awards $222,120 in Rhabdomyosarcoma Research Support
Megan Bugg, Childhood Cancer Warrior and Advocate
The Children's Cancer Therapy Development Institute has been awarded $222,120 by the Megan's Mission Foundation to advance three clinical research initiatives.
Since 2020, Megan Bugg and her supporters through Team Megan Bugg, now the Megan’s Mission Foundation, have raised more than $2,000,000 for childhood cancer research. This funding has driven significant progress, including initial work on Entinostat for RMS, which led to a phase 1 clinical trial. It also fueled investigation into the use of Immunotherapy for RMS patients and the development of the Citizen Scientist Project. This project explores repurposing existing drugs for RMS, informing the design of protein degrader therapeutics. Most recently, the Megan’s Mission Foundation funding enabled the hiring of cc-TDI’s first Megan Bugg Research Fellow, Alina Teuber PhD. Alina, a recent graduate of Dortmund University, joined cc-TDI to augment and accelerate cc-TDI’s mission of developing a new class of medicines, protein degrader therapeutics, as part of the Cancer Research UK Cancer Grand Challenge program. As a member of Team KOODAC, Alina will work with other cc-TDI lab member, Shefali Chauhan and NURIX THERAPEUTICS in the development of a clinical-grade protein degrader targeting the PAX3::FOXO1 protein in alveolar rhabdomyosarcoma.
The Megan’s Mission Foundation remains a steadfast partner of cc-TDI, exemplified by their ongoing support of the Megan Bugg Global Rhabdomyosarcoma Research Laboratory at cc-TDI. Throughout her fight, Megan was a staunch advocate for childhood cancer research. She gave voice to the voiceless so that other children and families would have better treatment options and ultimately better outcomes. Charles Keller, cc-TDI’s Scientific Director describes, “Megan spoke for every child touched by rhabdomyosarcoma, using her clear voice and poignant priorities. The Megan’s Mission Foundation carefully follows her purpose, and cc-TDI is honored to be part of her legacy.”
To learn more about cc-TDI’s research mission to move scientific discoveries to clinical trials for children with cancer, visit www.cc-TDI.org.
Erika Ellis
Children's Cancer Therapy Development Institute
5033499436 ext.
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
TikTok
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
